Literature DB >> 22562515

Antidiabetic drug metformin suppresses endotoxin-induced uveitis in rats.

Nilesh M Kalariya1, Mohammad Shoeb, Naseem H Ansari, Satish K Srivastava, Kota V Ramana.   

Abstract

PURPOSE: To investigate the therapeutic effects of metformin, a commonly used antidiabetic drug, in preventing endotoxin-induced uveitis (EIU) in rats.
METHODS: EIU in Lewis rats was developed by subcutaneous injection of lipopolysaccharide (LPS; 150 μg). Metformin (300 mg/kg body weight, intraperitoneally) or its carrier was injected either 12 hours before or 2 hours after LPS induction. Three and 24 hours after EIU, eyes were enucleated and aqueous humor (AqH) was collected. The MILLIPLEX-MAG Rat cytokine-chemokine magnetic bead array was used to determine inflammatory cytokines. The expression of Cox-2, phosphorylation of AMPK, and NF-κB (p65) were determined immunohistochemically. Primary human nonpigmented ciliary epithelial cells (HNPECs) were used to determine the in vitro efficacy of metformin.
RESULTS: Compared with controls, the EIU rat AqH had significantly increased number of infiltrating cells and increased levels of various cytokines and chemokines (TNF-α, MCP-1, IL-1β, MIP-1α, IL-6, Leptin, and IL-18) and metformin significantly prevented the increase. Metformin also prevented the expression of Cox-2 and phosphorylation of p65, and increased the activation of AMPK in the ciliary bodies and retinal tissues. Moreover, metformin prevented the expression of Cox-2, iNOS, and activation of NF-kB in the HNPECs and decreased the levels of NO and PGE2 in cell culture media.
CONCLUSIONS: Our results for the first time demonstrate a novel role of the antidiabetic drug, metformin, in suppressing uveitis in rats and suggest that this drug could be developed to prevent uveitis complications.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22562515      PMCID: PMC3390006          DOI: 10.1167/iovs.12-9432

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  59 in total

Review 1.  Understanding the role of aldose reductase in ocular inflammation.

Authors:  U C S Yadav; S K Srivastava; K V Ramana
Journal:  Curr Mol Med       Date:  2010-08       Impact factor: 2.222

Review 2.  Metformin in cancer therapy: a new perspective for an old antidiabetic drug?

Authors:  Issam Ben Sahra; Yannick Le Marchand-Brustel; Jean-François Tanti; Frédéric Bost
Journal:  Mol Cancer Ther       Date:  2010-05-04       Impact factor: 6.261

3.  Macrophage alpha1 AMP-activated protein kinase (alpha1AMPK) antagonizes fatty acid-induced inflammation through SIRT1.

Authors:  Zhenggang Yang; Barbara B Kahn; Hang Shi; Bing-Zhong Xue
Journal:  J Biol Chem       Date:  2010-04-26       Impact factor: 5.157

Review 4.  Metformin in polycystic ovary syndrome.

Authors:  Evanthia Diamanti-Kandarakis; Frangiskos Economou; Sotiria Palimeri; Charikleia Christakou
Journal:  Ann N Y Acad Sci       Date:  2010-09       Impact factor: 5.691

5.  AMPKalpha2 deletion causes aberrant expression and activation of NAD(P)H oxidase and consequent endothelial dysfunction in vivo: role of 26S proteasomes.

Authors:  Shuangxi Wang; Miao Zhang; Bin Liang; Jian Xu; Zhonglin Xie; Chao Liu; Benoit Viollet; Daoguang Yan; Ming-Hui Zou
Journal:  Circ Res       Date:  2010-02-18       Impact factor: 17.367

6.  Toxicity and toxicokinetics of metformin in rats.

Authors:  Michael P Quaile; David H Melich; Holly L Jordan; James B Nold; Jack P Chism; Joseph W Polli; Glenn A Smith; Melissa C Rhodes
Journal:  Toxicol Appl Pharmacol       Date:  2010-01-13       Impact factor: 4.219

7.  Sulphonylureas and cancer: a case-control study.

Authors:  Matteo Monami; Caterina Lamanna; Daniela Balzi; Niccolò Marchionni; Edoardo Mannucci
Journal:  Acta Diabetol       Date:  2008-12-10       Impact factor: 4.280

8.  Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy.

Authors:  Leigh A Cantrell; Chunxiao Zhou; Alberto Mendivil; Kimberly M Malloy; Paola A Gehrig; Victoria L Bae-Jump
Journal:  Gynecol Oncol       Date:  2009-10-12       Impact factor: 5.482

9.  Metformin inhibits nuclear factor kappaB activation and decreases serum high-sensitivity C-reactive protein level in experimental atherogenesis of rabbits.

Authors:  Song-Nan Li; Xiang Wang; Qiu-Tang Zeng; Yi-Bai Feng; Xiang Cheng; Xiao-Bo Mao; Tian-Hong Wang; He-Ping Deng
Journal:  Heart Vessels       Date:  2009-11-22       Impact factor: 2.037

10.  Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16.

Authors:  Gijs W D Landman; Nanne Kleefstra; Kornelis J J van Hateren; Klaas H Groenier; Rijk O B Gans; Henk J G Bilo
Journal:  Diabetes Care       Date:  2009-11-16       Impact factor: 19.112

View more
  20 in total

Review 1.  Metformin--mode of action and clinical implications for diabetes and cancer.

Authors:  Ida Pernicova; Márta Korbonits
Journal:  Nat Rev Endocrinol       Date:  2014-01-07       Impact factor: 43.330

2.  Metformin use and the risk of total knee replacement among diabetic patients: a propensity-score-matched retrospective cohort study.

Authors:  Francisco T T Lai; Benjamin H K Yip; David J Hunter; David P Rabago; Christian D Mallen; Eng-Kiong Yeoh; Samuel Y S Wong; Regina Ws Sit
Journal:  Sci Rep       Date:  2022-07-07       Impact factor: 4.996

Review 3.  Alzheimer's disease and type 2 diabetes: multiple mechanisms contribute to interactions.

Authors:  Anusha Jayaraman; Christian J Pike
Journal:  Curr Diab Rep       Date:  2014-04       Impact factor: 4.810

4.  Primed Mycobacterial Uveitis (PMU): Histologic and Cytokine Characterization of a Model of Uveitis in Rats.

Authors:  Kathryn L Pepple; Lauren Rotkis; Jennifer Van Grol; Leslie Wilson; Angela Sandt; Deborah L Lam; Eric Carlson; Russell N Van Gelder
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-12       Impact factor: 4.799

5.  AMP-activated protein kinase signaling protects oligodendrocytes that restore central nervous system functions in an experimental autoimmune encephalomyelitis model.

Authors:  Ajaib S Paintlia; Manjeet K Paintlia; Sarumathi Mohan; Avtar K Singh; Inderjit Singh
Journal:  Am J Pathol       Date:  2013-06-10       Impact factor: 4.307

Review 6.  Metformin and retinal diseases in preclinical and clinical studies: Insights and review of literature.

Authors:  Shivam V Amin; Saira Khanna; Seyedeh P Parvar; Lincoln T Shaw; David Dao; Seenu M Hariprasad; Dimitra Skondra
Journal:  Exp Biol Med (Maywood)       Date:  2022-01-22

7.  Metformin Down-regulates TNF-α Secretion via Suppression of Scavenger Receptors in Macrophages.

Authors:  Bobae Hyun; Seulmee Shin; Aeri Lee; Sungwon Lee; Youngcheon Song; Nam-Joo Ha; Kyung-Hea Cho; Kyungjae Kim
Journal:  Immune Netw       Date:  2013-08-26       Impact factor: 6.303

8.  Profiling and targeting of cellular bioenergetics: inhibition of pancreatic cancer cell proliferation.

Authors:  G Cheng; J Zielonka; D McAllister; S Tsai; M B Dwinell; B Kalyanaraman
Journal:  Br J Cancer       Date:  2014-05-27       Impact factor: 7.640

9.  Ocular inflammation in uveal tract in aged obese type 2 diabetic rats (Spontaneously Diabetic Torii fatty rats).

Authors:  Yusuke Kemmochi; Katsuhiro Miyajima; Takeshi Ohta; Tomohiko Sasase; Yuzo Yasui; Kaoru Toyoda; Kochi Kakimoto; Toshiyuki Shoda; Akihiro Kakehashi
Journal:  J Diabetes Res       Date:  2014-09-14       Impact factor: 4.011

10.  Effect of Metformin and Sitagliptin on Doxorubicin-Induced Cardiotoxicity in Rats: Impact of Oxidative Stress, Inflammation, and Apoptosis.

Authors:  Mina Thabet Kelleni; Entesar Farghaly Amin; Aly Mohamed Abdelrahman
Journal:  J Toxicol       Date:  2015-12-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.